Company / SG&A per Share
CRISPR Therapeutics AG SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.77
FY2025
5-year range
$0.77 / $1.31
FY2021-FY2025
Trend
-9.9%
vs FY2024
Sector context
#140 of 210
Health Care
What the data says
At $0.77, CRISPR Therapeutics AG's sg&a per share ranks #71 of 210 in the Health Care sector. SG&A per Share has declined for 3 consecutive years, from $1.31 in FY2022 to $0.77 in FY2025.
Based on SEC 10-K filings.
0.77 in FY2025 with a 5-year CAGR of -7.9%.
Improved from $0.95 to $0.77 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -16.2%
- 5-Year CAGR
- -7.9%
- 10-Year CAGR
- -
Sector benchmark
#71 of 210 in Health CareTop 33% of 210This company $0.77 Sector average $40.71
▼
-98.1% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's sg&a per share has declined for 3 consecutive years.
- In FY2025, sg&a per share decreased 9.9% year-over-year.
- Ranks #140 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.77 | -9.9% |
| FY2024 | $0.85 | -10.5% |
| FY2023 | $0.95 | -27.1% |
| FY2022 | $1.31 | +0.8% |
| FY2021 | $1.29 | +11.6% |
| FY2020 | $1.16 | -5.3% |
| FY2019 | $1.22 | +60.0% |
| FY2018 | $0.77 | +126.7% |
| FY2017 | $0.34 | -63.5% |
| FY2016 | $0.93 | -65.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026